ASGCT 29th Annual Meeting

May 11–15, 2026 | Thomas M. Menino Convention & Exhibition Center, Boston, MA

The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting is a primary forum for evaluating scientific progress in cellular and genetic therapeutics. Alloplex Biotherapeutics CEO and Scientific Founder, Dr. Frank Borriello, MD, PhD, will be attending the 29th Annual Meeting in Boston to review emerging data and engage with the scientific community.

Dr. Borriello’s participation focuses on tracking technical advancements in immune cell fitness and the regulatory requirements for next-generation autologous therapies. While attending as a participant, he will be assessing the current landscape of non-engineered approaches to oncology.

AREAS OF FOCUS:

• Scientific Review: Evaluating late-breaking data on immune cell persistence and tumor microenvironment modulation.
• Platform Integration: Analyzing the ENLIST immune cell training platform within the context of current cell therapy benchmarks.
• Technical Exchange: Connecting with peers to discuss the safety and multi-modal activity of SUPLEXA cells.

Individuals interested in discussing the ENLIST platform or potential technical collaborations are encouraged to reach out to the Alloplex team to coordinate a meeting during the conference.